|
A BRIEF REVIEW ON DIABETIC NEUROPATHY
|
|
| Author:
|
RASIKA NIKHADE, SUCHITA WAGHMARE, DR. SATISH KOSALGE
|
| Abstract:
|
Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects 40% of type 1 and type 2 diabetic patients. It increases the risk of death, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE) in the absence of other renal diseases. Diabetic neuropathy can be classified as peripheral, autonomic, proximal, or focal. A number of risk factors have been identified in the development of DN that include genetic susceptibility, elevated blood pressure, increased blood sugar, smoking and dyslipidemia. Moreover, various hyperglycemia-induced signaling mechanisms including increased formation of advanced glycation end products (AGEs), enhanced reactive oxygen species (ROS) generation and activation of protein kinase C (PKC). ACE inhibitors and angiotensin receptor blockers (ARBs) appeared to be successful in reducing the proteinuria and decreasing the creatinine doubling rate. These drugs decrease urinary albumin excretion (UAE) and the rate of progression from microalbuminuria to more advanced stages of DN and hence, the combination of these classes of drugs has been proposed as an alternative to treat DN. Replacing red meat with chicken in the usual diet reduced UAE by 46% and reduced total cholesterol, LDL cholesterol, and apolipoprotein B in microalbuminuric patients with type 2 diabetes in a 4-week study
|
| Keyword:
|
Diabetic nephropathy, urinary albumin excretion (UAE), ACE inhibitors.
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|